Kanya Rajangam
President at SENTI BIOSCIENCES, INC.
Net worth: 28 179 $ as of 2024-04-29
Profile
Kanya Rajangam is an Independent Director at Turnstone Biologics Corp.
since 2021 and the President at Senti Biosciences, Inc. since 2022.
Previously, Dr. Rajangam held positions as an Executive Director at Nektar Therapeutics in 2015, Senior Medical Director at Onyx Pharmaceuticals, Inc. from 2011 to 2015, Associate Medical Director at Exelixis, Inc. from 2008 to 2011, Chief Medical Officer at Cleave Therapeutics, Inc. from 2016 to 2017, Chief Medical Officer & Senior Vice President at Atara Biotherapeutics, Inc. from 2017 to 2018, and Chief Medical Officer at Nkarta, Inc. from 2019 to 2022.
Dr. Rajangam obtained a doctorate degree from St. John's Medical College in 1996.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
SENTI BIOSCIENCES, INC.
0.22% | 2024-01-31 | 101,000 ( 0.22% ) | 28 179 $ | 2024-04-29 |
| 2024-04-18 | 0 ( -.--% ) | - $ | 2024-04-29 |
Kanya Rajangam active positions
| Companies | Position | Start |
|---|---|---|
| SENTI BIOSCIENCES, INC. | President | 2024-05-13 |
| TURNSTONE BIOLOGICS CORP. | Director/Board Member | 2021-10-31 |
Turnstone Biologics, Inc.
 Turnstone Biologics, Inc. BiotechnologyHealth Technology Turnstone Biologics, Inc. develops bio-therapeutics for the treatment of cancer. It develops Maraba oncolytic viral immunotherapy, a platform representing a disruptive approach in the treatment of cancer. The company was founded by David Stojdl, Brian D. Lichty and John C. Bell and is headquartered in Ottawa, Canada. | Director/Board Member | 2011-10-31 |
Former positions of Kanya Rajangam
| Companies | Position | End |
|---|---|---|
| NKARTA, INC. | Chief Tech/Sci/R&D Officer | 2022-06-04 |
| ATARA BIOTHERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2018-08-31 |
Cleave Therapeutics, Inc.
 Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Chief Tech/Sci/R&D Officer | 2017-06-30 |
| NEKTAR THERAPEUTICS | Director/Board Member | 2015-04-30 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Chief Tech/Sci/R&D Officer | 2015-01-31 |
Training of Kanya Rajangam
| Northwestern University | Doctorate Degree |
| St. John's Medical College | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 6 |
|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Health Technology |
| EXELIXIS, INC. | Health Technology |
| NKARTA, INC. | Health Technology |
| NEKTAR THERAPEUTICS | Health Technology |
| SENTI BIOSCIENCES, INC. | Health Technology |
| TURNSTONE BIOLOGICS CORP. | Health Technology |
| Private companies | 3 |
|---|---|
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Turnstone Biologics, Inc.
Turnstone Biologics, Inc. BiotechnologyHealth Technology Turnstone Biologics, Inc. develops bio-therapeutics for the treatment of cancer. It develops Maraba oncolytic viral immunotherapy, a platform representing a disruptive approach in the treatment of cancer. The company was founded by David Stojdl, Brian D. Lichty and John C. Bell and is headquartered in Ottawa, Canada. | Health Technology |
- Stock Market
- Insiders
- Kanya Rajangam
